Saxenda or Wegovy for Weight Loss: Correcting the Biggest Misconception

The misconception worth clearing up first: they are not interchangeable

A common assumption is that Saxenda and Wegovy are essentially the same injection at different strengths, pick whichever is cheaper or easier to find. That framing is inaccurate in a way that matters clinically. Both activate the GLP-1 receptor, which slows gastric emptying and reduces appetite, but liraglutide (Saxenda) is a shorter-acting molecule that requires a daily injection and reaches a maintenance dose of 3mg. Semaglutide (Wegovy) has a longer half-life, is injected once a week, and the standard maintenance dose is 2.4mg, a number that can feel confusing until you understand these are different molecules with different potency per milligram.

The NHS patient information page for semaglutide and the equivalent liraglutide page both describe GI-led side-effect profiles (nausea, vomiting, diarrhoea, constipation) that are broadly similar in character, though the once-daily dosing of Saxenda means the body gets a repeated daily peak in drug concentration rather than one steady weekly exposure. Some people find that makes the nausea harder to manage. Others find a daily routine easier to stick to than a weekly one. Neither point is universal, it genuinely depends on the person.

A prescriber reviewing this decision is not just reading trial headlines. They are weighing your history, your other medicines, how you are likely to manage a daily versus weekly routine, and whether either licence applies to your specific situation. That conversation cannot happen without a clinical assessment.

What the trial results actually show when you compare them directly

The STEP 1 trial, published in the New England Journal of Medicine, found that adults taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks alongside lifestyle support, compared with roughly 2.4% in the placebo group. The equivalent landmark trial for liraglutide 3mg (SCALE Obesity and Prediabetes) reported average weight loss of approximately 5–7% over 56 weeks. Those are meaningfully different outcomes, and if you want to understand what drives them, our guide on whether Wegovy is better than Saxenda for weight loss walks through the clinical detail behind the numbers.

More recently, a dedicated higher-dose semaglutide pen at 7.2mg received MHRA approval in April 2026, with trial data suggesting average losses approaching 20% over 72 weeks among participants using that dose. Saxenda has no equivalent dose-escalation programme in development for weight management. If you want to explore how semaglutide is used across different products, including why Ozempic is not licensed for weight loss despite containing the same active ingredient, our page comparing Ozempic and semaglutide for weight loss covers that distinction clearly, and this page on Wegovy versus Ozempic explains the semaglutide landscape clearly, including why Ozempic is not licensed for weight loss despite containing the same active ingredient.

It is worth being transparent: trial populations are selected, conditions are controlled, and average figures do not predict your individual outcome. What they do reliably indicate is the direction and scale of the difference between these two medicines. NICE's appraisal process reached a similar conclusion, semaglutide received its own positive recommendation under NICE technology appraisal TA875, while liraglutide did not receive a NICE recommendation for weight management in England.

Saxenda is not dispensed by nume, here is what is, and why it matters

nume's pharmacy dispenses Wegovy (semaglutide) and Mounjaro (tirzepatide) for weight management. Saxenda is not part of our formulary. This is not a commercial quirk: it reflects where the evidence sits and what NICE has recommended for adults seeking weight-loss treatment in England.

Mounjaro is worth mentioning here because people searching between Saxenda and Wegovy sometimes are not yet aware of it. Tirzepatide is a dual GIP and GLP-1 receptor agonist (the only medicine in UK weight management to activate both pathways simultaneously) and the SURMOUNT-1 trial reported average weight reduction of around 20–21% at the highest dose over 72 weeks. If you want a clear side-by-side look at what separates it from semaglutide, the Mounjaro versus Wegovy comparison covers the evidence in plain terms.

For anyone still early in researching options, our weight-loss treatment overview sets out which medicines are licensed in the UK, what the eligibility criteria look like, and how private treatment through a regulated pharmacy works. And if Saxenda is what you have been prescribed elsewhere and you want to understand your options, speaking to a prescriber is the right next step rather than switching without advice. Unilateral changes between GLP-1 medicines carry clinical considerations that belong in a consultation, not a search result.

The practical question: which should you be considering, and what decides it?

Honestly, for most adults in the UK who meet the eligibility criteria, the clinical case for choosing semaglutide (Wegovy) over liraglutide (Saxenda) is now strong, and our full Saxenda vs Wegovy comparison sets out the differences in dosing, evidence and licensing side by side for anyone who wants the complete picture. Greater average weight loss, once-weekly dosing, a NICE recommendation, and an expanding licensed dose range all point in the same direction. Saxenda still has a role for patients who have previously responded well to it or who have specific clinical reasons to avoid semaglutide, but those are decisions made between a patient and their prescriber, not based on availability or price alone.

Eligibility for either requires a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not guarantee a prescription, a prescriber reviews the full picture. If you are unsure where you stand, our Wegovy information page sets out the licensed criteria in detail, or you can browse common questions our prescribers answer regularly.

If you have read enough and want a prescriber's view on your specific situation, you can start a free consultation with our clinical team. There is no commitment, no subscription, and the review is done the same day by a real GPhC-registered prescriber, not automated software. Speak to our prescribers and get a considered answer rather than another search result.